259 related articles for article (PubMed ID: 30518758)
1. NSD2 is a conserved driver of metastatic prostate cancer progression.
Aytes A; Giacobbe A; Mitrofanova A; Ruggero K; Cyrta J; Arriaga J; Palomero L; Farran-Matas S; Rubin MA; Shen MM; Califano A; Abate-Shen C
Nat Commun; 2018 Dec; 9(1):5201. PubMed ID: 30518758
[TBL] [Abstract][Full Text] [Related]
2. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
[TBL] [Abstract][Full Text] [Related]
3. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
4. Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
Yang P; Guo L; Duan ZJ; Tepper CG; Xue L; Chen X; Kung HJ; Gao AC; Zou JX; Chen HW
Mol Cell Biol; 2012 Aug; 32(15):3121-31. PubMed ID: 22645312
[TBL] [Abstract][Full Text] [Related]
5. NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-β/TGF-βRI/SMADs signaling.
Zhu L; Yu CL; Zheng Y
Biochem Biophys Res Commun; 2019 Nov; 519(3):489-496. PubMed ID: 31526565
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of NSD2 Suppresses Renal Cell Carcinoma Metastasis by Inhibiting Epithelial-Mesenchymal Transition.
Han X; Piao L; Yuan X; Wang L; Liu Z; He X
Int J Med Sci; 2019; 16(10):1404-1411. PubMed ID: 31692936
[No Abstract] [Full Text] [Related]
7. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
Ezponda T; Popovic R; Shah MY; Martinez-Garcia E; Zheng Y; Min DJ; Will C; Neri A; Kelleher NL; Yu J; Licht JD
Oncogene; 2013 Jun; 32(23):2882-90. PubMed ID: 22797064
[TBL] [Abstract][Full Text] [Related]
8. WHSC1/NSD2 regulates immune infiltration in prostate cancer.
Want MY; Tsuji T; Singh PK; Thorne JL; Matsuzaki J; Karasik E; Gillard B; Cortes Gomez E; Koya RC; Lugade A; Odunsi K; Battaglia S
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589522
[TBL] [Abstract][Full Text] [Related]
9. Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.
Wang JJ; Zou JX; Wang H; Duan ZJ; Wang HB; Chen P; Liu PQ; Xu JZ; Chen HW
Acta Pharmacol Sin; 2019 Aug; 40(8):1067-1075. PubMed ID: 30670815
[TBL] [Abstract][Full Text] [Related]
10. The prognostic impact of tumour NSD2 expression in advanced prostate cancer.
Stangl-Kremser J; Lemberger U; Hassler MR; Garstka N; Grubmüller B; Haitel A; Enikeev DV; Glybochko PV; Kramer G; Susani M; Shariat SF
Biomarkers; 2020 May; 25(3):268-273. PubMed ID: 32091270
[No Abstract] [Full Text] [Related]
11. The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription.
Kang HB; Choi Y; Lee JM; Choi KC; Kim HC; Yoo JY; Lee YH; Yoon HG
FEBS Lett; 2009 Jun; 583(12):1880-6. PubMed ID: 19481544
[TBL] [Abstract][Full Text] [Related]
12. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
13. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
Babbio F; Pistore C; Curti L; Castiglioni I; Kunderfranco P; Brino L; Oudet P; Seiler R; Thalman GN; Roggero E; Sarti M; Pinton S; Mello-Grand M; Chiorino G; Catapano CV; Carbone GM; Bonapace IM
Oncogene; 2012 Nov; 31(46):4878-87. PubMed ID: 22330138
[TBL] [Abstract][Full Text] [Related]
14. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
[TBL] [Abstract][Full Text] [Related]
15. Isoform-Specific Lysine Methylation of RORα2 by SETD7 Is Required for Association of the TIP60 Coactivator Complex in Prostate Cancer Progression.
Song H; Chu JW; Park SC; Im H; Park IG; Kim H; Lee JM
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32120841
[TBL] [Abstract][Full Text] [Related]
16. An
Lu X; Pan X; Wu CJ; Zhao D; Feng S; Zang Y; Lee R; Khadka S; Amin SB; Jin EJ; Shang X; Deng P; Luo Y; Morgenlander WR; Weinrich J; Lu X; Jiang S; Chang Q; Navone NM; Troncoso P; DePinho RA; Wang YA
Cancer Res; 2018 Jul; 78(14):3823-3833. PubMed ID: 29769196
[TBL] [Abstract][Full Text] [Related]
17. NSD2 circular RNA promotes metastasis of colorectal cancer by targeting miR-199b-5p-mediated DDR1 and JAG1 signalling.
Chen LY; Zhi Z; Wang L; Zhao YY; Deng M; Liu YH; Qin Y; Tian MM; Liu Y; Shen T; Sun LN; Li JM
J Pathol; 2019 May; 248(1):103-115. PubMed ID: 30666650
[TBL] [Abstract][Full Text] [Related]
18. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.
Eastham JA; Grafton W; Martin CM; Williams BJ
J Urol; 2000 Sep; 164(3 Pt 1):814-9. PubMed ID: 10953161
[TBL] [Abstract][Full Text] [Related]
19. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
Yu J; Yu J; Rhodes DR; Tomlins SA; Cao X; Chen G; Mehra R; Wang X; Ghosh D; Shah RB; Varambally S; Pienta KJ; Chinnaiyan AM
Cancer Res; 2007 Nov; 67(22):10657-63. PubMed ID: 18006806
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.
Asangani IA; Ateeq B; Cao Q; Dodson L; Pandhi M; Kunju LP; Mehra R; Lonigro RJ; Siddiqui J; Palanisamy N; Wu YM; Cao X; Kim JH; Zhao M; Qin ZS; Iyer MK; Maher CA; Kumar-Sinha C; Varambally S; Chinnaiyan AM
Mol Cell; 2013 Jan; 49(1):80-93. PubMed ID: 23159737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]